Qu – which according to Parsa is the fruit of a collaboration between a global team of experienced AI scientists, ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...

Full Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage. AstraZeneca PLC ...

Apollo Tyres, Thermax, PI Industries, Deepak Nitrite, Bayer CropScience, Brigade Enterprises, NBCC (India), Wockhardt, ...

Other pharmaceutical players such as Roche, Amgen, Pfizer, AstraZeneca and Boehringer also have obesity drugs in the pipeline ...

AstraZeneca's plan to invest £450 million in vaccine R&D in the UK is currently on hold due to ongoing talks with the British ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca boss Pascal Soriot (pictured)) threw his weight behind its Chinese business despite the recent arrest of its boss ...

AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about a ...

Merck and AstraZeneca's MEK inhibitor Koselugo (selumetinib) showed significant improvement in adult neurofibromatosis type 1 ...